Lenvatinib, an angiogenesis inhibitor, inhibits VEGF and tumor fibroblast growth factor signaling pathways in unresectable HCC.25 The synergistic effect of the combination can inhibit tumor growth more effectively. Here, VEGFA is linked to neoplasm.